Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$-1.06
EPS est.
$-0.77
EPS surprise
-37.31%
1-day move
+1.40%
Mirum Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still rose by 1.4%, indicating that investors may have had lower expectations or are optimistic about future developments. The lack of revenue data and management commentary leaves some uncertainty about the company's current performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.06 | N/A | -37.31% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for rare liver diseases. With a market cap of $6 billion, it plays a significant role in the health care sector, particularly as demand for specialized treatments continues to grow.
Last quarter
In Q1-2026, Mirum reported a significant earnings miss with an EPS of -$13.43 compared to the estimated -$0.40. Despite this, the stock rose 4.04% the following day, indicating some investor optimism.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
-681.12%
Avg 1-day reaction
+1.41%
Overall expectations for Mirum's upcoming earnings are cautious given the recent history of earnings misses. Investors will be closely watching for any signs of improvement.
Bull case
If Mirum can demonstrate improved financial metrics and effective management of its R&D expenditures, it could signal a turnaround in performance, leading to a positive market reaction.
Bear case
Conversely, if the company continues to report significant losses and fails to provide a clear path to profitability, it could lead to further declines in stock value.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
Given the significant earnings miss last quarter, any improvement in EPS will be closely scrutinized to gauge the company's financial health.
Q2
How much is being allocated to R&D this quarter?
Investors will want to know if Mirum is maintaining or increasing its investment in R&D, which is crucial for its long-term growth and product pipeline.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate Mirum's potential for a turnaround, as recent operational changes could lead to improved efficiency and reduced losses.
Supporting evidence
The company's recent stock price increase despite poor earnings suggests some investor optimism.
Options pricing indicates a significant potential move, reflecting uncertainty that could work in favor of a surprise positive outcome.
Key risk
If R&D spending shows a clear commitment to innovation, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is debating whether Mirum can turn around its financial performance after a series of disappointing earnings.
Bull confirmed if
A reduction in EPS losses to below -$10.00 would indicate improved cost management and operational efficiency.
Bear confirmed if
Continued losses exceeding -$15.00 EPS would suggest that the company is struggling to control expenses.
What the market is pricing for the move.
Implied Move
±37.56%
Historical Avg
±1.5%
The options market is pricing in a substantial potential move, reflecting high uncertainty around the upcoming earnings report.
Options are pricing ±37.6% while MIRM has averaged ±1.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
56.0%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
111.77%
of float
Insider
1.29%
of float
Holders
442
institutions
Top Holders· as of Jun 2026
Frazier Life Sciences Management, L.P.
7,679,684 sh · $619.3M
11.83%
Flat
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Mirum beats expectations, history suggests the stock could rise by around 1.33%, confirming a positive shift in investor sentiment.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await clearer guidance.
Miss
Should the company miss again, history indicates a potential decline of about 0.31%, further eroding investor confidence.
The lines on the call that would change the story.
Jupiter Topco LLC
5,909,184 sh · $476.5M
9.10%
100.0%
Blackrock Inc.
4,390,063 sh · $354.0M
6.76%
14.1%
FMR, LLC
3,670,314 sh · $296.0M
5.65%
86.8%
Price (T.Rowe) Associates Inc
2,655,607 sh · $214.1M
4.09%
54.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.